Histone Methyltransferase
Histone modifications play critical roles in regulating both global and stage-specific gene expression. Methylation on histones H3K4, H3K36 and H3K79 is generally associated with gene activation, whereas methylation on histones H3K9 and H3K27 is generally associated with gene repression. Histone lysine methylation is dynamically regulated by site-specific methyltransferases and demethylases. EZH2 (the catalytic subunit of PRC2) is responsible for the methylation of H3K27 in cells.
DOT1L is a histone H3 lysine 79 methyltransferase whose inhibition increases the yield of induced pluripotent stem cells (iPSCs). EPZ-5676 is a potent and selective DOT1L inhibitor.
Crucial to PRC2 activity, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) tri-methylates lysine 27 of histone 3 (H3K27me3), leading to chromatin condensation and transcriptional repression.
Histone Methyltransferase Isoform Specific Products
-
Histone Methyltransferase
(368)
View all products
-
EZH1
(11)
View all products
-
EZH2
(85)
View all products
-
DOT1L
(21)
View all products
-
SMYD2
(9)
View all products
-
SMYD3
(9)
View all products
-
SUV39H2/
KMT1B (4)View all products
-
EHMT2/
G9a/ (32)KMT1C View all products
-
EHMT1/
GLP/ (20)KMT1D View all products
-
ASH1L/
KMT2H (4)View all products
-
SETDB1/
KMT2G (4)View all products
-
SETD2/
KMT3A (5)View all products
-
NSD2/
MMSET/ (16)WHSC1 View all products
-
NSD3/
WHSC1L1 (4)View all products
-
SETD7/
KMT7 (6)View all products
-
SETD8/
KMT5A (5)View all products
-
PRMT1
(25)
View all products
-
PRMT3
(17)
View all products
-
PRMT4
(19)
View all products
-
PRMT5
(64)
View all products
-
PRMT6
(23)
View all products
-
PRMT7
(8)
View all products
-
PRMT8
(13)
View all products
All Product Categories
-
Histone Methyltransferase Inhibitors
(517)
View all products
-
Histone Methyltransferase Agonists
(5)
View all products
-
Histone Methyltransferase Antagonists
(11)
View all products
-
Histone Methyltransferase Activators
(5)
View all products
-
Histone Methyltransferase Modulators
(4)
View all products
-
Histone Methyltransferase Chemical
(1)
View all products
-
Histone Methyltransferase Inducers
(3)
View all products
-
Histone Methyltransferase Degraders
(68)
View all products
-
Histone Methyltransferase Controls
(8)
View all products
-
Histone Methyltransferase Ligands
(16)
View all products
-
Histone Methyltransferase Related Products (687)
Related Products (687)
-
Antibodies (84)
-
Histone Methyltransferase Isoform Comparison
-
CARM1-IN-4
0 ImagesCat. No.: HY-161334CAS No.: 2878481-07-1CARM1-IN-4 (compound 11f) is a potent CARM1 inhibitor with IC50s of 9 nM and 56 nM for CARM1 and PRMT1, respectively. CARM1-IN-4 displays significant anti-proliferative effects on colorectal cancer cell lines. CARM1-IN-4 effectively inhibits the methyltransferase activity of CARM1 and prevents methylation of downstream proteins. CARM1-IN-4 induces apoptosis and shows antitumor activity.
-
CSV0C018875 hydrochloride
0 ImagesCat. No.: HY-133031ACAS No.: 474084-56-5CSV0C018875 hydrochloride is a G9a (EHMT2) inhibitor that inhibits G9a activity. CSV0C018875 can effectively inhibit G9a activity in both enzyme and cell-based assays, and its toxicity is much lower than that of the known G9a inhibitor BIX-01294. CSV0C018875 binds tightly to the active site cavity of G9a, thereby improving the binding firmness and prolonging the residence time of the compound, further enhancing the inhibitory effect of G9a. CSV0C018875 has the potential to improve its ADME (absorption, distribution, metabolism and excretion) and pharmacodynamic properties through further optimization.
-
Dot1L-IN-7
0 ImagesCat. No.: HY-146724CAS No.: 2580940-76-5Dot1L-IN-7 (compound 25) is a potent and selective disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 of 1.0 μM. Dot1L-IN-7 selectively killed Mixed Lineage Leukemia (MLL)-AF9 without showing any effect on the growth of E2A-HLF cells.
-
EPZ033294
0 ImagesEPZ033294 is an inhibitor of SYMD2 (IC50 is 3.9 nM). SYMD2 itself has catalytic activity and can methylate the lysine residue of BTF3 to BTF3me1, which was experimentally demonstrated by detecting an IC50 of 2.9 nM for inhibition of BTF3ME1 by SYMD2, indicating an active inhibition of SYMD2 by EPZ033294. EPZ033294 (0-50 µM) has an inhibitory effect on SYMD2 and a concentration-dependent inhibitory effect in 293T.
-
C199
0 ImagesCat. No.: HY-174445CAS No.: 3107801-96-4C199 is a PROTAC degrader targeting PRMT4 (DC50 = 106 nM). C199 shows high selectivity for PRMT4 over other protein arginile methyltransferases. C199 exhibits strong cell degradation ability. C199 induces apoptosis in MM cell lines. C199 efficiently clears PRMT4 protein via the VHL-proteasome pathway. C199 has a relatively long half-life and shows strong anti-multiple myeloma (MM) tumor activity.
-
(S)-PFI-2 hydrochloride
0 ImagesCat. No.: HY-110196CAS No.: 1627607-88-8(S)-PFI-2 hydrochloride is an inhibitor of lysine methyltransferase SETD7 and is approximately 500-fold more active than its enantiomer (R)-PFI-2. (R)-PFI-2 is a cofactor-dependent and substrate-competitive inhibitor. (R)-PFI-2 can occupy the substrate peptide binding groove of SETD7 (including the catalytic lysine binding channel) and interact with the cofactor The donor methyl group is in direct contact. However, (S)-PFI-2 was not observed to have the same interaction as (R)-PFI-2.
-
NPD13668
0 ImagesCat. No.: HY-122640CAS No.: 864819-54-5NPD13668 is an EZH2-mediated gene silencing modulator. NPD13668 inhibits EZH2/PRC2 (polycomb repressive complex 2) activity. NPD13668 reactivates the expression of silenced H3K27me3 target genes together with depletion of the H3K27me3 modification. NPD13668 can be used for the study of prostate cancer and ovarian cancer.
-
TB22
0 ImagesCat. No.: HY-162939TB22 is a non-nucleoside inhibitor of DOT1LR231Q, possessing anticancer activity. TB22 inhibits the malignant phenotype of lung cancer cells carrying the R231Q mutation through the MAPK/ERK signaling pathway, and can be used for lung cancer research.
-
EZH2-IN-7
0 ImagesCat. No.: HY-143616CAS No.: 2659225-28-0EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259).
-
WAY-260022
0 ImagesCat. No.: HY-10427CAS No.: 850692-43-2Synonyms: NRI-022WAY-260022 is a selective norepinephrine reuptake inhibitor with potent inhibitory activity on norepinephrine reuptake. WAY-260022 exhibits excellent selectivity in inhibiting serotonin and dopamine transporters. WAY-260022 also showed oral efficacy in a rat model of thermoregulatory dysfunction.
-
RK-0133114
0 ImagesCat. No.: HY-152775ARK-0133114 is a G9a inhibitor and a R-enantiomer of RK-701 (HY-152775). RK-0133114 inhibits G9a with an IC50 value of 3.7 μM. RK-0133114 can be used for the research of sickle cell disease (SCD).
-
CDK9/EZH2-IN-2
0 ImagesCat. No.: HY-189422CDK9/EZH2-IN-2 is a potent dual CDK9 and EZH2 inhibitor with an IC50 of 8.9 nM against EZH2. CDK9/EZH2-IN-2 inhibits anti-apoptotic proteins and induces DNA damage by blocking the activity of CDK9 and EZH2, ultimately leading to tumor cell apoptosis. CDK9/EZH2-IN-2 can be used for research on diffuse large B-cell lymphoma.
-
PROTAC EZH2 Degrader-19
0 ImagesCat. No.: HY-181320CAS No.: 2653338-65-7PROTAC EZH2 Degrader-19 (compound 6) is a is a PROTAC protein degrader targeting EZH2 with an IC50 of 15.00 nM. PROTAC EZH2 Degrader-19 induces strong degradation of all PRC2 subunits (EZH2, SUZ12, EED, RbAp48) in a concentration- and time-dependent manner.PROTAC EZH2 Degrader-19 exhibits antiproliferative effects in cancer cells.PROTAC EZH2 Degrader-19 can be used for the research of cancer.
-
PRMT5-IN-49
0 ImagesCat. No.: HY-169708CAS No.: 428853-17-2PRMT5-IN-49 (Compound 4b16) is an inhibitor of PRMT5.
-
NSD2-IN-4
0 ImagesCat. No.: HY-155818CAS No.: 3035028-80-6NSD2-IN-4 is a potent and selective NSD2-SET inhibitor. NSD2-IN-4 has the potential for NSD2-related diseases.
-
PRMT5-IN-11
0 ImagesCat. No.: HY-139823ACAS No.: 2567564-33-2PRMT5-IN-11 is a promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex in the (sub)micromolar range.
